Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils Specifically, the approval covers patients already on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) or on a combination of LABA and LAMA if ICS is not appropriate. Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ) are jointly developing dupilumab under a global collaboration agreement. The EMA is the first regulatory authority in the world to approve Dupixent for COPD patients. Read Next: Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market Dupixent is the first new treatment approach for COPD in more than a decade and a new option for approximately 220,000 adults in the EU. The approval represents the sixth approved indication for Dupixent in the EU and the seventh approved indication globally. The approval is based on results from t
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Dupixent “addresses current gap” in COPD biologics landscape [Yahoo! Finance]Yahoo! Finance
- Three Solid Euronext Paris Dividend Stocks With Yields Up To 7.9% [Yahoo! Finance]Yahoo! Finance
- French State Investment Firm Eyes Stake in Sanofi Consumer Unit [Yahoo! Finance Canada]Yahoo! Finance Canada
- French State Investment Firm Eyes Stake in Sanofi Consumer Unit [BNN Bloomberg (Canada)]BNN Bloomberg
- Kidney Transplant Market to Grow at a 3.3% CAGR from 2024 to 2034, Fueled by Healthcare Spending and Renal Calculi Retrieval Devices Landscape | TMR [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 7/2/24 - Form 6-K
- 6/28/24 - Form 11-K
- 6/28/24 - Form 11-K
- SNY's page on the SEC website